LAVA Therapeutics NV (LVTX) — Strategic Asset Allocation Index
LAVA Therapeutics NV (LVTX) has a Strategic Asset Allocation Index of 5.1% as of September 2023. Strategic assets (PP&E of $2.78 Million plus long-term investments of $-) total $2.78 Million, measured against net assets of $54.60 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. See LAVA Therapeutics NV net asset quality index to measure how much of total assets are equity-financed.
SAAI
Strategic Assets
PP&E
Net Assets
LAVA Therapeutics NV Strategic Asset Allocation Index (2019–2022)
This chart shows how LAVA Therapeutics NV's Strategic Asset Allocation Index has evolved across 4 annual periods from 2019 to 2022. As of September 2023, the index stands at 5.1%, representing strategic assets of $2.78 Million against net assets of $54.60 Million USD. For live market cap and overall valuation, see LVTX market cap overview.
Annual Strategic Asset Allocation Index for LAVA Therapeutics NV (2019–2022)
The table below presents the year-by-year Strategic Asset Allocation Index for LAVA Therapeutics NV from 2019 to 2022, covering 4 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. See LVTX net assets for net asset value and shareholders' equity analysis.
| Year | SAAI | Strategic Assets (USD) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2022 | 2.4% | $2.08 Million | $2.08 Million | $- | $86.04 Million | ▲ +0.8 pp |
| 2021 | 1.6% | $1.95 Million | $1.95 Million | $- | $118.37 Million | ▼ -14.3 pp |
| 2020 | 16.0% | $1.22 Million | $1.22 Million | $- | $7.62 Million | ▼ -1.6 pp |
| 2019 | 17.5% | $1.02 Million | $1.02 Million | $- | $5.84 Million | — |